Hemerion develops innovative therapeutic solutions for oncology, at the crossroads of surgery, biology and photonics.
In addition to our scientific and medical skills, our team brings together all the clinical, regulatory and financial talents needed to bring our therapies to market worldwide.
Hemerion commits to gender equality
Our team is convinced that this diversity has a positive impact on our creativity, solidarity and performance.
Leadership
Maximilien Vermandel
PhD, Physicist
Chief Executive Officer
A medical physicist by training, Maximilien Vermandel founded Hemerion in 2020, after more than 20 years’ experience in management and medical research (Lille University Hospital, Inserm, General Electric Healthcare…).
He is in charge of Hemerion’s global strategy and business development.
Clément Dupont
PhD, Physicist
Chief Technological Officer
Designer of the medical devices used in the first clinical trial evaluating Hemerion technology, Clément Dupont oversees our R&D endeavors and the development and technological optimization of our solutions, working closely with the regulatory and clinical teams.
Michel Andraud
MSc, Business School
Chief Financial Officer
Michel Andraud has extensive experience in the financial management of innovative and industrial companies, particularly in the healthcare sector (Orphalan, Ribonexus, Kiji Therapeutics).
In particular, he is in charge of Hemerion’s financial and equity management.
Executive Management
Research & Development
Under the direction of the Chief Technology Officer, the R&D department is developing applications for Hemerion technology in the treatment of several types of cancer, with the aim of improving the performance of existing therapeutic solutions. It also works to improve the solutions clinically tested in the treatment of glioblastoma.
Mélanie Rose, PhD
Director of Scientific Innovation and Pipeline Expansion
With a PhD in Oncology and Cancer Biology, Mélanie Rose is a specialist in immuno-oncology and innovative treatments for brain tumors. Mélanie Rose coordinates, oversees and implements translational, basic and clinical research activities, with the aim to expand the pipeline of clinical projects and evaluate the potential of Pentalafen®/Heliance® combination therapy for treating cancers after surgical resection.
Clinical Affairs
The Clinical Affairs Department structures, designs and organizes Hemerion’s clinical studies.
Everardo Saad, MD
Medical Director
As a medical oncologist contributing to the design or analysis of more than 100 clinical trials, Dr. Everardo Saad has over 25 years of experience in clinical research. He advises and guides Hemerion’s clinical and regulatory affairs teams on medical issues, compliance strategy, protocol development and interpretation, and data credibility for FDA and EMA submissions.
Antoine Mequignon, MSc
Manager
Antoine Mequignon has an international background, having set up and managed some twenty large-scale clinical trials in human health (Amplity Health, Rhythm Pharmaceuticals, Hays, Sanofi, etc.). He directs Hemerion’s clinical development in close collaboration with the sites and investigators.
Regulatory Affairs
The Regulatory Affairs Department ensures that Hemerion’s operations comply with international health regulations. It is the main point of contact for the European and American health agencies (EMA and FDA).
Luciola Jáuregui Teniente, PharmD
Manager
A pharmacist by training, Luciola Jáuregui Teniente is a specialist in regulatory issues in the healthcare sector. With extensive international experience (Altogen, Cenexi, Sanofi, Cooper, Innothera), she heads Hemerion’s department in charge of relations with American and European health agencies. She also manages Hemerion’s molecules pharmaceutical development and manufacturing.
Quality Assurance
This department ensures quality management for the development of Hemerion’s therapeutic solutions (medical devices and drugs): certification, compliance and vigilance.
Cécile Formentel, MSc
Manager
A graduate of ILIS in healthcare engineering, Cécile Formentel has developed extensive expertise in quality assurance in various healthcare sectors: analytical laboratories, healthcare institutions, sterile medical devices, electromedical devices, operating room equipment and implants.
She oversees the certification and continuous improvement of Hemerion’s activities, and provides our team with a vision that is essential to the success of Market Access operations and the industrialization of our solutions.
Scientific Board
Pr. Nicolas Reyns
PhD, MD, Neurosurgery
Co-Founder
- Head of the neurosurgery oncology dept of the Univ. Hosp. of Lille
- Co-inventor of the Hemerion technology
- Over 100 scientific papers
Pr. Serge Mordon
PhD, Physics
Co-Founder
- Full time researcher in laser therapy over 40 years at Inserm
- Former Director of OncoThAI Lab (Inserm U1189)
- Over 500 scientific papers
Pr. Costas G. Hadjipanayis
PhD, MD, Neurosurgery
- Director, UPMC Center for Image-Guided Neurosurgery
- Former Director of Neurosurgical Oncology for the Mount Sinai Health System (NYC, NY, USA)
- Over 100 scientific papers